Compare Travere Therapeutics Inc. Common Stock (TVTX) vs Twilio Inc (TWLO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Travere Therapeutics Inc. Common Stock vs Twilio Inc — how do they compare? Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B), while Twilio Inc trades at $268.99 (market cap $43.25B). The key difference: Twilio Inc is far larger — about 8.9× Travere Therapeutics Inc. Common Stock's market cap, and Twilio Inc is trading nearer its 52-week high, Travere Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Travere Therapeutics Inc. Common Stock for 0 Days and Twilio Inc for 56 Days on average.
| TVTX | TWLO | |
|---|---|---|
Market Cap | $4.88B | $43.25B |
Volume | 1,668,577 | 1,616,308 |
Sector | Health | Technology |
52-Week High | $67.52 | $301.27 |
52-Week Low | $26.79 | $106.23 |
Typical Hold Time | 0 Days | 56 Days |
Enterprise Value | $5.01B | $41.65B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Twilio stock trades at $271.12, down 4.08% today, amid mixed signals. The technical outlook is bullish based on moving averages, with key support at $268. Fundamentally, revenue grew to $5.07B in 2025, with net income turning positive at $33.83M after years of losses. Recent news highlights its upcoming addition to the S&P 500 index effective October 6, 2026, a positive catalyst for institutional interest.
The outlook is cautiously optimistic given strong analyst support (76.9% buy ratings) and a consensus price target of $257.59, though the stock trades above this level. Risks include high valuation multiples (P/E 38.89) and competitive pressures in customer engagement software. Earnings beats in recent quarters support growth momentum, but investors should weigh rich valuations against execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →About Twilio Inc
Twilio Inc. is a cloud-based communication platform-as-a-service company offering communication building blocks that allow for a fully customized customer engagement experience spanning voice, video, chat, and SMS messaging. It does this through various application programming interfaces, or APIs, and prebuilt solution applications aimed at improving customer engagement. The company leverages its Super Network, a global network of carrier relationships, to facilitate high-speed, cost-effective communication.
Read more on TWLO →
